3 completed, 1 recruiting, 1 suspended, 1 unknown. 7 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Recruiting 1, Suspended 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Fluvoxamine: new trials by email Literature Review of Fluvoxamine trials Research Report on Fluvoxamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluvoxamine for Long COVID-19 Fluvoxamine - Long COVID | Phase 2 / Phase 3 | Completed | Washington University School of Medicine | 191 | 2023-05-15 | 2026-10-07 |
| Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia Fluvoxamine, Placebo - COVID-19, Olfactory Disorder | Phase 2 | Withdrawn | Washington University School of Medicine | 2021-12-14 | 2022-03-11 | |
| Fluvoxamine for Adults With Mild to Moderate COVID-19 Fluvoxamine, Placebo - Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus Infection | Phase 2 | Suspended | Asan Medical Center | 400 | 2021-01-16 | 2021-04-19 |
| Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients Placebo, Fluvoxamine - Covid19 | Phase 2 | Completed | SigmaDrugs Research Ltd. | 66 | 2020-11-27 | 2022-08-23 |
| Pragmatic Trial of Obsessive-compulsive Disorder Sertraline 200 milligram(mg), Sertraline 300 milligram(mg), Fluvoxamine - Obsessive-Compulsive Disorder | Phase 2 | Recruiting | Shanghai Mental Health Center | 1600 | 2020-09-22 | 2025-05-15 |
| A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection Fluvoxamine, Placebo - COVID 19, Coronavirus | Phase 2 | Completed | Washington University School of Medicine | 152 | 2020-04-10 | 2021-07-09 |
| A Clinical Trial of Fluvoxamine for Melancholia Fluvoxamine - Depressive Disorder, Endogenous Depression | Phase 2 | Unknown | Lingjiang Li | 150 | 2019-08-01 | 2022-04-12 |
COVID-19 (3) · Coronavirus Infections (2) · Depressive Disorder (1) · Obsessive-Compulsive Disorder (1) · Olfaction Disorders (1) · Post-Acute COVID-19 Syndrome (1)
Washington University School of Medicine (3) · Asan Medical Center (1) · Lingjiang Li (1) · Shanghai Mental Health Center (1) · SigmaDrugs Research Ltd. (1)
United States (3) · China (2) · Hungary (1) · South Korea (1)
Eric J Lenze, MD (1) · Eric Lenze, MD (1) · Jay F Piccirillo, MD (1) · Lingjiang Li, MD (1) · Yong Pil Chong, M.D., Ph.D. (1) · Zhen Wang, PhD,MD (1)
PMID 33180097, PMID 33240091, PMID 35384422, PMID 35651818, PMID 37304432